For patients with fat malabsorption who require enteral feeding...

Hydrolyze Fats, Normalize Absorption of Fatty Acids

RELiZORB mimics the function of pancreatic lipase and delivers absorbable fats to your patients.

In a clinical studies, use of RELiZORB was shown to normalize DHA/EPA plasma concentrations to levels consistent with a reference range based on healthy subjects as shown in the literature (please see IFU for full description of the study and references).

Severity and Impact
of Fat Malabsorption

Understand the Devastating Consequences

RELiZORB Achieves
Efficient Fat Hydrolysis

See the Data

Starting RELiZORB
Is Simple

View Downloadable Forms

Image of RELiZORB digestive enzyme cartridge used for patients with fat malabsorption who require enteral feeding.

RELiZORB is indicated for use in pediatric patients (ages 5 years and above) and adult patients to hydrolyze fats in enteral formula.

RELiZORB is indicated for use in pediatric patients

(ages 5 years and above) and adult patients to hydrolyze fats in enteral formula.

RELiZORB is for use with enteral feeding only; do not connect to intravenous or other medical tubing
Medications should not be administered through RELiZORB
RELiZORB is available for sale only in the US

For patients with fat malabsorption who require enteral feeding...

Hydrolyze Fats, Normalize Absorption of Fatty Acids

RELiZORB is indicated for use in pediatric patients (ages 5 years and above) and adult patients to hydrolyze fats in enteral formula.

RELiZORB is indicated for use in pediatric patients

(ages 5 years and above) and adult patients to hydrolyze fats in enteral formula.

HCP

Final Sequance (vimeo 720p)